Hubei Biocause Pharmaceutical - Asset Resilience Ratio

Latest as of September 2024: 0.78%

Hubei Biocause Pharmaceutical (000627) has an Asset Resilience Ratio of 0.78% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥2.24 Billion

≈ $327.52 Million USD Cash + Short-term Investments

Total Assets

CN¥285.15 Billion

≈ $41.73 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2002–2023)

This chart shows how Hubei Biocause Pharmaceutical's Asset Resilience Ratio has changed over time. Check Hubei Biocause Pharmaceutical strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Hubei Biocause Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 000627 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥2.24 Billion	0.78%
Total Liquid Assets	CN¥2.24 Billion	0.78%

Asset Resilience Insights

Limited Liquidity: Hubei Biocause Pharmaceutical maintains only 0.78% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hubei Biocause Pharmaceutical Industry Peers by Asset Resilience Ratio

Compare Hubei Biocause Pharmaceutical's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Prudential plc F:PRU2	Insurance - Life	0.00%
HDFC Life Insurance Company Limited NSE:HDFCLIFE	Insurance - Life	0.15%
Brighthouse Financial Inc NASDAQ:BHF	Insurance - Life	33.32%
Challenger Ltd AU:CGF	Insurance - Life	2.14%
Hapvida Participações e Investimentos S.A. SA:HAPV3	Insurance - Life	10.15%
Prudential plc LSE:PRU	Insurance - Life	2.65%
Clearview Wealth Ltd AU:CVW	Insurance - Life	22.11%
Nobleoak Life Ltd AU:NOL	Insurance - Life	11.03%

Annual Asset Resilience Ratio for Hubei Biocause Pharmaceutical (2002–2023)

The table below shows the annual Asset Resilience Ratio data for Hubei Biocause Pharmaceutical.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.60%	CN¥1.80 Billion ≈ $263.16 Million	CN¥301.94 Billion ≈ $44.18 Billion	-0.13pp
2022-12-31	0.72%	CN¥2.08 Billion ≈ $304.74 Million	CN¥288.60 Billion ≈ $42.23 Billion	-0.38pp
2021-12-31	1.10%	CN¥2.91 Billion ≈ $425.46 Million	CN¥263.90 Billion ≈ $38.62 Billion	-0.39pp
2020-12-31	1.49%	CN¥3.56 Billion ≈ $521.43 Million	CN¥239.40 Billion ≈ $35.03 Billion	+0.41pp
2019-12-31	1.08%	CN¥2.21 Billion ≈ $323.66 Million	CN¥205.27 Billion ≈ $30.04 Billion	-1.89pp
2017-12-31	2.97%	CN¥4.16 Billion ≈ $609.44 Million	CN¥140.42 Billion ≈ $20.55 Billion	+2.15pp
2008-12-31	0.81%	CN¥16.08 Million ≈ $2.35 Million	CN¥1.98 Billion ≈ $289.67 Million	+0.57pp
2007-12-31	0.24%	CN¥3.22 Million ≈ $470.89K	CN¥1.32 Billion ≈ $193.82 Million	+0.13pp
2006-12-31	0.11%	CN¥1.34 Million ≈ $196.08K	CN¥1.17 Billion ≈ $170.82 Million	-0.01pp
2002-12-31	0.12%	CN¥1.36 Million ≈ $199.30K	CN¥1.09 Billion ≈ $159.56 Million	--

pp = percentage points

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life

Market Cap

$1.13 Billion

CN¥7.75 Billion CNY

Market Cap Rank

#8235 Global

#1884 in China

Share Price

CN¥1.58

Change (1 day)

+0.00%

52-Week Range

CN¥1.39 - CN¥1.58

All Time High

CN¥10.45